Angelo Delmonte

9.7k total citations
145 papers, 2.7k citations indexed

About

Angelo Delmonte is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Angelo Delmonte has authored 145 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Pulmonary and Respiratory Medicine, 91 papers in Oncology and 29 papers in Molecular Biology. Recurrent topics in Angelo Delmonte's work include Lung Cancer Treatments and Mutations (86 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Lung Cancer Research Studies (31 papers). Angelo Delmonte is often cited by papers focused on Lung Cancer Treatments and Mutations (86 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Lung Cancer Research Studies (31 papers). Angelo Delmonte collaborates with scholars based in Italy, United States and United Kingdom. Angelo Delmonte's co-authors include Lucio Crinò, Cristiana Sessa, Paola Ulivi, Giuseppe Bronte, Gianluca Spitaleri, Matteo Canale, Filippo de Braud, Daniele Calistri, Rita Chiari and Francesca Toffalorio and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Angelo Delmonte

140 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Angelo Delmonte Italy 27 1.6k 1.4k 907 689 356 145 2.7k
Eun Kyung Cho South Korea 29 2.1k 1.4× 2.0k 1.5× 756 0.8× 397 0.6× 309 0.9× 134 3.6k
Teresa Gamucci Italy 28 688 0.4× 2.3k 1.7× 827 0.9× 723 1.0× 155 0.4× 128 3.5k
Kun He United States 27 1.3k 0.8× 2.0k 1.5× 835 0.9× 475 0.7× 214 0.6× 53 3.2k
Anh T. Le United States 20 2.3k 1.5× 2.1k 1.5× 1.4k 1.5× 869 1.3× 491 1.4× 56 3.5k
S. Kakolyris Greece 32 925 0.6× 1.9k 1.4× 1.0k 1.1× 816 1.2× 185 0.5× 90 3.0k
Helena Linardou Greece 27 1.2k 0.8× 1.8k 1.3× 899 1.0× 653 0.9× 237 0.7× 87 2.8k
Masahiro Tabata Japan 35 2.9k 1.9× 2.9k 2.1× 1.3k 1.4× 606 0.9× 230 0.6× 225 4.5k
In Hae Park South Korea 31 1.7k 1.1× 2.3k 1.7× 532 0.6× 1.4k 2.0× 504 1.4× 114 3.6k
Taito Esaki Japan 29 1.4k 0.9× 2.1k 1.6× 743 0.8× 235 0.3× 353 1.0× 184 3.3k
Michael Millward Australia 25 1.1k 0.7× 1.7k 1.3× 1.1k 1.3× 331 0.5× 142 0.4× 43 2.9k

Countries citing papers authored by Angelo Delmonte

Since Specialization
Citations

This map shows the geographic impact of Angelo Delmonte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angelo Delmonte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angelo Delmonte more than expected).

Fields of papers citing papers by Angelo Delmonte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angelo Delmonte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angelo Delmonte. The network helps show where Angelo Delmonte may publish in the future.

Co-authorship network of co-authors of Angelo Delmonte

This figure shows the co-authorship network connecting the top 25 collaborators of Angelo Delmonte. A scholar is included among the top collaborators of Angelo Delmonte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angelo Delmonte. Angelo Delmonte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Normanno, Nicola, Alessandro Morabito, Anna Maria Rachiglio, et al.. (2025). Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?. Nature Reviews Clinical Oncology. 22(3). 215–231. 7 indexed citations
2.
Citarella, Fabrizio, Kazuki Takada, Priscilla Cascetta, et al.. (2024). Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung). Journal of Translational Medicine. 22(1). 714–714. 3 indexed citations
3.
Bertolini, Federica, Elisabetta Petracci, Stefania Bettelli, et al.. (2023). Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project.. Journal of Clinical Oncology. 41(16_suppl). e21077–e21077.
4.
Verlicchi, Alberto, Matteo Canale, Elisa Chiadini, et al.. (2023). The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer. Life. 13(9). 1915–1915. 1 indexed citations
5.
Massa, Ilaria, Flavia Foca, Angelo Delmonte, et al.. (2022). Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. Cancers. 14(18). 4481–4481. 4 indexed citations
6.
7.
Ahn, M-J., Hye Ryun Kim, James Chih‐Hsin Yang, et al.. (2020). 1304P Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L. Annals of Oncology. 31. S843–S844. 1 indexed citations
8.
Landi, Lorenza, Marcello Tiseo, Lukas C. Heukamp, et al.. (2019). P1.14-03 Molecular Determinants for Lorlatinib Activity in ROS1 Positive NSCLC: Results of the Prospective PFROST Trial. Journal of Thoracic Oncology. 14(10). S553–S553. 1 indexed citations
9.
Massa, Ilaria, et al.. (2019). PCN80 REAL-WORLD HEALTHCARE COSTS IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER IN ITALY. Value in Health. 22. S451–S451. 1 indexed citations
10.
D’Arcangelo, M., Davide Tassinari, Filippo de Marinis, et al.. (2019). P2.01-15 Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET). Journal of Thoracic Oncology. 14(10). S644–S644. 9 indexed citations
11.
Monti, Manlio, Danila Diano, Angelo Delmonte, et al.. (2017). Bordetella bronchiseptica pneumonia in a patient with lung cancer; a case report of a rare infection. BMC Infectious Diseases. 17(1). 644–644. 10 indexed citations
12.
13.
Canale, Matteo, Elisabetta Petracci, Angelo Delmonte, et al.. (2016). Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clinical Cancer Research. 23(9). 2195–2202. 196 indexed citations
14.
Bidoli, Paolo, Rita Chiari, Annamaria Catino, et al.. (2016). Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy. Annals of Oncology. 27. vi425–vi425. 18 indexed citations
15.
Catania, Chiara, Edoardo Botteri, Massimo Barberis, et al.. (2015). Molecular Features and Clinical Outcome of Lung Malignancies in Very Young People. Future Oncology. 11(8). 1211–1221. 11 indexed citations
16.
Delmonte, Angelo, Marita Mariotti, Emanuela Scarpi, et al.. (2015). Venous thromboembolic events in advanced adenocarcinoma of the lung: impact on prognosis according to platinum therapies and presence of driver mutations. Annals of Oncology. 26. vi83–vi83. 2 indexed citations
17.
Soria, J.C., Filippo de Braud, Rastilav Bahleda, et al.. (2014). Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Annals of Oncology. 25(11). 2244–2251. 147 indexed citations
18.
Sessa, Cristiana, Patricia LoRusso, Anthony W. Tolcher, et al.. (2013). Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(17). 4832–4842. 42 indexed citations
19.
Pas, Tommaso De, Francesca Toffalorio, Michela Manzotti, et al.. (2011). Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations. Journal of Thoracic Oncology. 6(11). 1895–1901. 106 indexed citations
20.
Delmonte, Angelo & Cristiana Sessa. (2008). Molecule-targeted agents in endometrial cancer. Current Opinion in Oncology. 20(5). 554–559. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eun Kyung Cho Breakdown of academic impact, for papers by Teresa Gamucci Breakdown of academic impact, for papers by Kun He Breakdown of academic impact, for papers by Anh T. Le Breakdown of academic impact, for papers by S. Kakolyris Breakdown of academic impact, for papers by Helena Linardou Breakdown of academic impact, for papers by Masahiro Tabata Breakdown of academic impact, for papers by In Hae Park Breakdown of academic impact, for papers by Taito Esaki Breakdown of academic impact, for papers by Michael Millward
Rankless by CCL
2026